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Abstract Introduction: We investigated whether event-related potentials (ERP) collected in outpatient set-
tings and analyzed with standardized methods can provide a sensitive and reliable measure of the
cognitive deficits associated with early Alzheimer’s disease (AD).
Methods: A total of 103 subjects with probable mild AD and 101 healthy controls were recruited at
seven clinical study sites. Subjects were tested using an auditory oddball ERP paradigm.
Results: Subjects with mild AD showed lower amplitude and increased latency for ERP features
associated with attention, working memory, and executive function. These subjects also had
decreased accuracy and longer reaction time in the target detection task associated with the ERP test.
Discussion: Analysis of ERP data showed significant changes in subjects with mild AD that are
consistent with the cognitive deficits found in this population. The use of an integrated hardware/soft-
ware system for data acquisition and automated data analysis methods make administration of ERP
tests practical in outpatient settings.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Multicenter clinical trial; Event-related potentials; Oddball paradigm; Early stage Alzheimer’s disease; Outpatient
settings; Automated ERP data analysis
1. Background
Despite the emergence of putative biomarkers for Alz-
heimer’s disease (AD) [1], clinical diagnostic accuracy is sub-
optimal [2]. A sensitive and reliable physiological measure of
the cognitive deficits associated with AD could provide
insight in the cognitive physiology of the disease, and help
with diagnosis, and assessment of severity and progression.
Event-related potentials (ERP) reflect well-characterized
brain responses to sensory, motor, and cognitive events [3].
As such, ERP methods are well suited to detect and quantify
the cognitive deficits associated with AD [4]. ERP have been
found to be altered in AD beginning in the very early stages
of the disease. ERP tests on young presymptomatic individ-
uals who carry mutations in the presenilin-1, and amyloid
precursor protein genes show significant changes in ERP
patterns years before the onset of behavioral symptoms
and the development of AD [5,6]. ERP have shown
potential utility as biomarkers of disease progression and
P.M.D. has received grants from and served as advisor to companies in
this field, including Neuronetrix. He also owns stock in several health care/
technology companies whose products are not discussed here. He is coin-
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subsequent conversion to dementia in individuals with mild
cognitive impairment (MCI). ERP responses to auditory
stimuli contain discriminative information that predicts
which MCI patients are likely to progress to AD [7], and pa-
tients with amnestic MCI that are at high risk of conversion
to AD have abnormal ERP during a word repetition task [8].
ERP have also been shown to reliably track the cognitive
decline associated with AD progression. ERP markers of
cognitive function are increasingly altered in longitudinal
studies on MCI and AD patients [9,10]. Finally, ERP are
sensitive to the effects of cognitive enhancers currently
used for the treatment of AD. ERP measures are reliable
instruments for the assessment of the cognitive response to
cholinesterase inhibitors such as donepezil, while the
effects of the selective N-methyl-D-aspartate (NMDA)
antagonist memantine on ERP correlate with changes in
mini-mental state examination (MMSE) score [11–13].
Although the potential of ERP as a sensitive and reliable
cognitive biomarker for AD has been known for a long time
(for review, see [14–16]), the promise of this technique has
not been yet fully realized through wide adoption of ERP
in clinical use. Primary reasons have been the lack of
standardization of ERP acquisition and data analysis
techniques, and the impracticality of conducting ERP tests
in clinical environments on actual patients. Recent
advances in electronics and analysis algorithms have made
it possible to administer ERP tests in a practical manner.
There is now a need for large population-based studies that
can confirm the usefulness of ERP as cognitive biomarkers
for AD outside the laboratory [6].
In our multicenter clinical study, we investigated whether
ERP collected in an outpatient setting and analyzed with
automated, standardized methods can achieve results equiv-
alent to those reported from academic laboratories and pro-
vide a sensitive and reliable measure of the cognitive deficits
associated with early AD.
2. Materials and methods
2.1. Study participants
A total of 103 subjects with probable mild AD and 101
healthy controls (HC) aged between 60 and 90 years were re-
cruited at seven clinical study sites. The study (ClinicalTrials.
gov number NCT00938665) was approved by institutional
review boards for each site, and a written informed consent
was obtained from each study participant.
2.2. Subjects screening
All study subjects received a thorough medical history
and neurologic examination. General inclusion criteria for
the study included a modified Hachinski score4 and a geri-
atric depression scale (GDS) short form score5. Exclusion
criteria were the use of antidepressants other than selective
serotonin uptake inhibitors, major psychiatric disorders,
and clinically significant neurologic diseases other than
AD. Subjects taking sedatives and/or memory dietary sup-
plements were asked to suspend them for the 72 hours before
screening and testing.
The diagnosis of probable AD was made on the basis of
the National Institute of Neurological and Communication
Disorders and the Stroke-Alzheimer’s Disease and Related
Disorders Association criteria [17]. The inclusion criteria
for the AD cohort were designed to recruit subjects in the
early stages of the disease and encompassed anMMSE score
between 21 and 26, a clinical dementia rating (CDR) score of
0.5, 1, or 2, and an education adjusted score on the delayed
recall of the Wechsler logical memory II subscale of 3 for
0–7 years of education, 5 for 8–15 years of education, and
9 for 16 or more years of education.
Inclusion criteria for the HC cohort were an MMSE score
of 27 and above, a CDR score of 0, and an education
adjusted score on the delayed recall of the Wechsler logical
memory II subscale of4 for 0–7 years of education,6 for
8–15 years of education, and 10 for 16 or more years of
education.
2.3. Experimental paradigm
Subjects who met inclusion criteria at screening were
tested using a three-stimulus oddball paradigm (for review,
see [18,19]).
Stimuli comprised of standard tones (1000 Hz), target
tones (2000 Hz), and unexpected distractor tones (white
noise) that were played with probabilities of .75, .15, and
.10. Tones were presented in pseudorandom order, so that
target and distractor tones were never presented sequentially
[20]. Subjects were instructed to respond to the target stimuli
by pressing a button with their dominant hand. For each test,
between 300 and 400 stimuli were presented binaurally
through insert ear phones at 70-dB volume. The tone duration
for each stimulus was 100 ms with rise and fall times of
10 ms. The interstimulus interval was randomized between
1.5 and 2 s. During the test, subjects sat comfortably in a chair
in an office room under regular lighting conditions. One HC
and four mild AD subjects whowere unable to follow instruc-
tions were excluded from all statistical analyses.
2.4. Testing procedures and data analysis
Electroencephalographic (EEG) activity was recorded
from 7 electrode sites (Fz, Cz, Pz, F3, P3, F4, and P4) of
the international 10-20 system [21] using a COGNISION
Headset (Neuronetrix). Electrodes were referenced to aver-
aged mastoids (M1, M2), and Fpz served as the common
electrode. The headset used for data collection has been vali-
dated to perform reliable ERP recordings when skin contact
impedance is,70 kU, a practical requirement for recording
in standard office environments. Impedance was automati-
cally checked at all electrodes after each target or distractor
tone, and was kept below this limit throughout each test.
Data were collected from 2240 to 1000 ms around the
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stimuli, digitized at 125 Hz, and bandpass filtered from 0.3 to
35 Hz. An automatic artifact threshold detection limit of
6100 mV was set for the tests. Trial sets of a deviant tone
and the immediately preceding standard tones (epoch sets)
with artifacts exceeding the threshold were rejected in real
time and immediately repeated.
Trial averaging and extraction of ERP measures were auto-
matically performed by the COGNISION System software
Fig. 1. Grand average ERPs for standard, target, and distractor stimuli in mild AD and HC subjects. ERP features for each stimulus are shown at the electrode
site where they were found to be more prominent. Abbreviations: ERP, event-related potentials; HC, healthy controls; AD, Alzheimer’s disease.
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(Neuronetrix). EEG data from each trial were baseline corrected
using the prestimulus period [6,22] and averaged according
to stimulus. For standard tones, only the trials immediately
preceding target and distractor stimuli were averaged.
During data preprocessing, recordings that exceeded two
times the root mean square value (RMS) for the EEG test
data or with wrong button presses were rejected and excluded
from averaging. ERP waves that averaged less than 20 trials
after preprocessing were eliminated from all analyses [23].
Peak amplitude of the ERP features was measured as the
difference between the mean prestimulus baseline and
maximum peak amplitude. Peak latency was defined as the
time point corresponding to the maximum amplitude and
was calculated relative to stimulus onset [24,25]. P50 and
N100 were measured from all stimuli. P200 was measured
from standard and target tones. N200, P3b, and slow wave
were measured from the target tone and P3a from the
distractor tone (Fig. 1).
TheP50ERPfeaturewasdefinedas themaximumpositivity
between 24 and 72 ms poststimulus, N100 was the maximum
negativity between 70 and 130ms, P200 themaximumpositiv-
itybetween180and235ms, andN200 themaximumnegativity
between 205and315ms.TheP3awas defined as themaximum
positivity between 325 and 500 ms, and the P3b as the
maximum positivity between 325 and 580 ms. Finally, the
slow wave was the maximum negativity between 460 and
680ms.All timewindowswere determined by inspecting indi-
vidual averages and group grand averages [26].
The feature extraction algorithm used for the analysis
defined a maximum positivity as the highest point in the
measurement window that was surrounded on both sides
by lower voltage. If a maximum positivity was not present
in the time window chosen for an ERP feature, the algorithm
would not select a peak for that channel.
Together with peaks amplitude and latency, the algorithm
for data analysis also calculated mean amplitude for the ERP
features of interest, defined as the average voltage over the
specified measurement window for each ERP feature [27].
Finally, accuracy and reaction time of button presses were
also analyzed. Accuracy was calculated as the percent of
correct responses to target tones, whereas false alarms indi-
cated button presses to nontargets. Reaction time was calcu-
lated as the time from stimulus onset to button press. Median
reaction times were calculated for each subject to limit the
influence of any outlier reaction times [5].
2.5. Statistical analysis
Group comparisons were analyzed using c2 test and Stu-
dent t test for categorical and quantitative variables, respec-
tively. Age was significantly different between mild AD and
HC groups and was used as a covariate in all statistical com-
parisons where data correlated with age. P values,.05 were
considered significant. When multiple comparisons were
performed, a Bonferroni correction was applied to control
for type I error and the adjusted P values were reported.
Correlations between ERP component values were analyzed
using Pearson correlation coefficients.
3. Results
3.1. Demographics and clinical data
There were no significant differences in gender and edu-
cation between study groups. Age, however, was higher on
average in subjects with mild AD (t 5 2.94, P , .05).
Statistical comparison of clinical data between groups
showed, as expected, lower MMSE (t 5 228.93, P , .01),
lower Wechsler logical memory (t 5 220.28, P , .01 and
t 5 228.38, P , .01 for immediate and delayed recall,
respectively), and higher CDR (t 5 30.54, P , .01) scores
in subjects with mild AD. These subjects also had a higher
GDS (t 5 7.32, P , .01), whereas the Hachinski score was
similar between groups (Table 1).
3.2. ERP test
Morphology of the grand average waves for standard,
target, and distractor stimuli was different between groups
(Fig. 1). The differences were larger for target and distractor
tones, and for the late cognitive responses than for the early
sensory measures (Supplementary Fig. 1).
Statistical comparisons for ERP features in mild AD
versus HC are listed in Table 2. Age correlated with N100,
P3b, and P3a latency measures (R2 .0.05), and was used
as covariate in comparisons for these ERP measures.
Analysis of ERP features for the standard tone showed
lower N100 amplitude (t 5 6.25, P , .01) and P200 ampli-
tude (t523.39, P, .01) in the mild AD group. This group
of subjects also had higher P50 (t5 3.68, P, .01) and lower
N100 average amplitudes (t 5 5.50, P , .01) than HC.
Comparisons for the target tone indicated that subjects with
mild AD had lower N100 amplitude (t5 4.88, P, .01), lower
P3b amplitude (t 5 25.65, P , .01), and a more negative
N200 peak (t 5 23.38, P , .01) than HC. This group of
Table 1
Demographic and clinical characteristics of study participants
Characteristics HC (n 5 100) AD (n 5 99)
Age 73.2 6 0.71 76.2 6 0.74*
Male (%) 40 48.5
Education (y) 14.9 6 0.29 14.4 6 0.32
MMSE 29.1 6 0.08 23.4 6 0.19**
CDR 0.0 6 0.0 0.9 6 0.03**
WMS-R logical memory
Immediate recall 14.6 6 0.31 5.3 6 0.33**
Delayed recall 13.7 6 0.33 2.1 6 0.24**
GDS 0.8 6 0.11 2.3 6 0.16**
Hachinski 0.6 6 0.07 0.6 6 0.07
Abbreviations: HC, healthy controls; AD, mild Alzheimer’s disease;
MMSE, mini-mental state examination; CDR, clinical dementia rating;
WMS-R, Wechsler memory scale-revised; GDS, geriatric depression
scale; SEM, standard error of the mean.
NOTE. Data are represented as mean 6 SEM. *P , .05 and **P , .01
compared with HC after Bonferroni correction.
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subjects also showed a delay in the late cognitive measures
with longer latencies for the N200 (t 5 3.43, P , .01), P3b
(t5 2.66,P, .05), and slowwave (t5 2.88,P, .05). Finally,
data for average amplitude showed lower N100 (t 5 4.99,
P , .01), lower N200 (t 5 24.73, P , .01), and a tendency
to lower P3b (t 5 22.47, P , .1) in subjects with mild AD,
thus closely resembling amplitude data.
When ERP features for the distractor tone were analyzed,
statistical comparisons showed decreased amplitude (t522.55,
P , .05) and longer latency (t 5 2.83, P , .05) for the P50
in subjects with mild AD. These subjects also had smaller
N100 and P3a amplitudes (t 5 4.24, P , .01 and
t 5 28.07, P , .01) and average amplitudes (t 5 3.57,
P , .01 and t 5 210.68, P , .01, respectively).
A follow-up single-channel analysis at midline electrodes
for the ERP features that were statistically different between
groups showed that changes in N100 measures were pro-
nounced at the frontal and central electrode sites, whereas
changes in P3a and P3b ERP features were more prominent
at the central and parietal electrodes (Table 3).
When performance in the target detection task associated
with the ERP test was analyzed, there were significant differ-
ences between groups. Subjects with mild AD had a lower
percentage of correct responses to target tones (t 5 24.61,
P , .01), a higher number of button presses to nontargets
(t 5 3.43, P , .01), and a longer reaction time for accurate
button presses than HC (t 5 2.4, P , .05; Table 4).
Finally, analysis of correlations across ERP features that
were significantly different between groups showed overall
low Pearson coefficients. Exceptions were N100 measures
across different stimuli, and correlations among amplitude
and average amplitude for the same ERP measure
(Supplementary Table 1).
4. Discussion
Study results showed significant differences in ERP
measures between subjects with mild AD and HC. The group
differences included both ERP features extracted from the
average waves for the test stimuli and behavioral measures
from the target detection task.
The most widely investigated and best understood
changes in ERP in mild AD are related to the P3b, or classic
P300. This ERP feature is elicited when a deviant stimulus is
associated with a task and reflects an update in working
memory (for review of the neuropsychological origins of
the P3b, please see [28]). The P3b amplitude is determined
by the amount of attentional resources allocated when work-
ing memory is updated [29]. The P3b latency reflects stim-
ulus evaluation and classification speed [30,31]. The
majority of studies that have looked at differences in P3b
between AD subjects and HC have found that P3b
amplitude was typically smaller, and P3b latency was
longer in subjects with AD (for an overview, please see
[32]). Consistent with our results, when subjects were
administered an auditory oddball paradigm where discrimi-
nation of standard and target tones was easy, group differ-
ences were larger for P3b amplitude than latency [32].
Together with the P3b, other significant changes in the
ERP wave for the target tone included longer latencies for
the N200 and slow wave, and a more negative N200 in sub-
jects with mild AD.
The N200 is a negative peak that immediately precedes
the P3b. This ERP feature is linked to the cognitive processes
of stimulus identification and distinction [33] and its peak la-
tency has been shown to correlatewith measures of executive
function and attention [34]. Published studies have reported
delayed latency [34] and smaller amplitude [9] for the N200
in AD. Indeed, N200 latency has proven useful in separating
AD subjects from subjects with MCI and HC [34], and N200
amplitude has been used in combination with P300 latency to
track longitudinal changes in overall cognitive function in
MCI [9]. Our findings offer further evidence that both the
peak latency and amplitude are affected in AD.
The slow wave is a negative deflection that follows the
P3b. This ERP feature has frontal and central scalp
Table 2
ERP features in HC and mild AD
ERP feature Stimulus
Amplitude (mV) Latency (ms) Average amplitude (mV)
HC AD HC AD HC AD
P50 Standard 2.77 6 0.08 2.95 6 0.08 44.8 6 0.4 44.3 6 0.4 0.29 6 0.06 0.60 6 0.06**
N100 Standard 27.23 6 0.14 26.00 6 0.14** 93.0 6 0.4 95.2 6 0.5 24.56 6 0.11 23.73 6 0.11**
P200 Standard 5.26 6 0.14 4.64 6 0.12** 214.5 6 1.0 211.7 6 0.8 3.44 6 0.11 3.14 6 0.10
P50 Target 2.79 6 0.09 2.79 6 0.09 42.6 6 0.5 43.2 6 0.5 0.36 6 0.06 0.52 6 0.07
N100 Target 26.64 6 0.14 25.63 6 0.15** 95.2 6 0.5 98.6 6 0.6 24.25 6 0.12 23.43 6 0.12**
P200 Target 4.49 6 0.18 4.86 6 0.18 202.8 6 0.9 201.2 6 0.9 2.35 6 0.13 2.61 6 0.14
N200 Target 20.31 6 0.17 21.10 6 0.16** 251.1 6 1.3 257.9 6 1.5** 2.84 6 0.14 1.93 6 0.13**
P3b Target 6.03 6 0.20 4.42 6 0.20** 396.0 6 2.8 419.6 6 3.3* 1.92 6 0.16 1.40 6 0.13w
Slow wave Target 22.54 6 0.20 22.65 6 0.18 563.6 6 2.5 575.4 6 3.2* 20.02 6 0.15 0.19 6 0.15
P50 Distractor 3.70 6 0.09 3.35 6 0.10* 45.2 6 0.6 47.6 6 0.6* 1.18 6 0.08 1.26 6 0.09
N100 Distractor 25.34 6 0.14 24.47 6 0.15** 101.1 6 0.5 103.9 6 0.5 22.84 6 0.11 22.21 6 0.12**
P3a Distractor 5.88 6 0.19 3.63 6 0.20** 417.3 6 2.4 419.8 6 3.0 3.40 6 0.15 1.26 6 0.13**
Abbreviations: ERP, event-related potentials; HC, healthy controls; AD, mild Alzheimer’s disease; SEM, standard error of the mean.
NOTE. Data are represented as mean 6 SEM. wP , .1; *P , .05; and **P , .01 compared to HC after Bonferroni correction.
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distribution [5] and reflects a final stage of stimulus evalua-
tion [35]. The slow wave amplitude correlates with task de-
mands and it is inversely correlated to stimulus detection
accuracy, suggesting that an increase in peak amplitude
might reflect the need for further stimulus processing. The
slow wave latency is affected by task difficulty, and the rela-
tive ease of categorizing events in an oddball test probably
accounts for the early onset and short duration of the slow
wave in this ERP paradigm [35]. In our study, slow wave la-
tency was delayed in mild AD. Our data are consistent with a
previous report of increased slow wave latency in MCI [9]
and suggest that AD subjects might require more time for
stimulus processing than HC.
Contrary to the P3b, reports on the effects of AD and other
dementias on P3a amplitude and latency are scarce, and the
findings have been to some extent inconsistent [26,36,37].
The P3a is associated with engagement of attention and
processing of novelty [28]. The peak amplitude is a measure
of focal attention and has been shown to positively correlate
with executive function [38]. The P3a latency reflects orien-
tation to a nontarget deviant stimulus [16]. Our data show a
reduction of P3a amplitude in subjects with mild AD that is
consistent with reports of decreased attention and executive
function in neuropsychological testing in this population
[39]. Moreover, the large group differences in P3a amplitude
together with reports of a decline in attention and some exec-
utive skills very early in the disease [40,41] suggest that this
ERP feature could be a useful measure of cognitive deficit
from the preclinical stage of AD.
Like for the P3a, N100 amplitude also showed a large
decrease in the mild AD group. The effect was present in
response to all stimuli. Although the N100 reflects bottom-
up information such as stimulus characteristics [42,43], it is
modulated by attention and memory-related variables
[44,45]. Thus, it is possible that the lower amplitude of the
N100 in subjects with mild AD might reflect attention and
memory deficits in these subjects. Indeed, neuropathologic
studies show that sensory cortices are typically spared until
the advanced stages ofAD [46].Adecrease inN100 amplitude
could reflect changes in regulatory inputs from brain regions
that are involved in higher cognitive processes and are more
directly affected by the disease in its early stages. For example,
the prefrontal cortex and the nucleus basalis have been shown
to modulate auditory cortical responses to sound [47,48].
In addition to changes in the ERP wave, subjects with mild
AD also showed decreased performance in the behavioral task
associated with the ERP test. This group of subjects had lower
button press accuracy and longer reaction time. Previous work
by Polich and Corey-Bloom [32] has shown increased
response time and error rate in AD patients across different
auditory and visual oddball paradigms.Our data confirm these
findings in patients tested in outpatient settings and suggest
that results from the behavioral task of the ERP test could
help discriminate subjects with mild AD from healthy aging.
Scientific literature on the neuropsychology of ERP mea-
sures indicates that the different ERP features collected with
an oddball paradigm provide complimentary information
[49]. Indeed, in our study, correlations between ERP features
that showed significant group differences were overall quite
low, suggesting that data from a single test can be used to
assess deficits in several cognitive domains affected by AD.
Automated data analysis methods such as the ones used in
the present study make extraction of multiple ERP features
from data sets practical, thus providing a fast and reliable
method to look at multiple sensory and cognitive measures.
Although correlations across different ERP features were
generally low, correlations between each feature amplitude
and average amplitude were high. These data suggest that
an ERP feature average amplitude likely shares the same
functional interpretation with its amplitude, and can be
used as a proxy measure to confirm amplitude data, or in sit-
uations where an ERP peak might be difficult to identify.
5. Conclusion
Analysis of data collected from this large multicenter
study closely reflects findings reported from research
Table 3
Statistically significant differences between groups at single midline
electrodes
ERP
feature Stimulus Type Loc. HC AD P value
P3a Distractor Av. Ampl. Cz 4.03 6 0.42 1.32 6 0.35 ,.001
P3a Distractor Av. Ampl. Pz 4.31 6 0.34 2.22 6 0.32 ,.001
P3a Distractor Amplitude Cz 6.96 6 0.50 3.98 6 0.49 ,.001
P3a Distractor Amplitude Pz 7.01 6 0.42 4.54 6 0.46 ,.001
N100 Standard Amplitude Fz 29.69 6 0.31 28.01 6 0.35 .001
N100 Standard Amplitude Cz 28.78 6 0.33 27.20 6 0.32 .002
P3a Distractor Av. Ampl. Fz 2.76 6 0.42 0.77 6 0.41 .003
N100 Standard Av. Ampl. Fz 26.47 6 0.24 25.35 6 0.28 .007
P3b Target Amplitude Pz 7.36 6 0.39 5.74 6 0.38 .010
N100 Standard Av. Ampl. Cz 25.64 6 0.24 24.60 6 0.26 .012
N100 Target Av. Ampl. Cz 25.26 6 0.28 24.12 6 0.29 .015
N100 Standard Amplitude Pz 24.82 6 0.26 23.87 6 0.24 .025
N100 Target Amplitude Cz 28.03 6 0.37 26.74 6 0.36 .028
N100 Target Amplitude Pz 24.32 6 0.25 23.39 6 0.26 .034
N100 Distractor Amplitude Fz 26.85 6 0.39 25.39 6 0.44 .039
P3b Target Latency Pz 395.8 6 6.2 419.3 6 7.6 .049
Abbreviations: Loc., electrode location according to the 10/20 system;
HC, healthy controls; AD, mild Alzheimer’s disease; Av. Ampl, average
amplitude; SEM, standard error of the mean.
NOTE. Data are represented as mean 6 SEM. P values shown are
adjusted using the Bonferroni correction for multiple comparisons. Only
significant differences between groups are shown.
Table 4
HC and mild AD performance in the behavioral task of the ERP test
Behavioral measure HC AD
Button press accuracy (%) 94.1 6 1.1 82.2 6 2.3**
False alarms (%) 1.1 6 0.2 4.9 6 1.1**
Median reaction time (ms) 458.6 6 11.4 499.5 6 12.6*
Abbreviations: HC, healthy controls; AD,mild Alzheimer’s disease; ERP,
event-related potentials; SEM, standard error of the mean.
NOTE. Data are represented as mean 6 SEM. *P , .05 and **P , .01
compared with HC after Bonferroni correction.
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laboratories on changes in ERP measures in subjects with
AD. In addition, the study also offers insights on additional
ERP differences in HC versus mild AD that to our knowledge
had not yet been reported, or for which there did not seem to
be a consensus. Follow-ups will include a classification-based
analysis to measure sensitivity and specificity of ERP in diag-
nosing subjects with early AD in outpatient settings and a
separate study to correlate ERP measures with neuropsycho-
logical tests that are widely used to assess cognitive status.
Data for the study were collected in outpatient settings
from nonspecialized personnel. Our results suggest that the
use of an integrated hardware/software system for ERP
testing and automated data analysis tools can address the
practical limitations that have hindered a wide adoption of
electrophysiological measures as useful biomarkers for AD
outside research laboratories.
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RESEARCH IN CONTEXT
1. Systematic review: Since the 1970s, a large scientific
literature has shown that event-related potentials
(ERP) can provide a sensitive, physiological measure
of the cognitive deficits associated with Alzheimer’s
disease (AD). However, the use of ERP in AD has
been mostly limited to studies conducted at a single
site and/or on a limited number of subjects. There is a
need for large population-based studies that can
confirm the usefulness of ERP as biomarkers for AD
in outpatient settings.
2. Interpretation: Findings from our multicenter clinical
study show that ERP collected with standard
methods and analyzed using automated data analysis
tools provide a sensitive and practical measure of the
cognitive deficits associated with early AD.
3. Future directions: Additional analysis of the ERP
data from the study, using classification-based ma-
chine learning approaches, will provide further
insight on the sensitivity and specificity of ERP in
diagnosing subjects with early AD in outpatient
settings.
References
[1] Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW,
et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s
pathological cascade. Lancet Neurol 2010;9:119–28.
[2] Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clin-
ical diagnosis of Alzheimer disease at National Institute on Aging Alz-
heimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012;
71:266–73.
[3] Hillyard SA. Imaging Techniques: Event-related potentials (ERPs)
and cognitive processing. In: Squire LR, ed. New Encycl. Neurosci.
Oxford: Academic Press; 2009. p. 13–8.
[4] Katada E, Sato K, Ojika K, Ueda R. Cognitive event-related potentials:
Useful clinical information in Alzheimer’s disease. Curr Alzheimer
Res 2004;1:63–9.
[5] Golob E, Ringman JM, Irimajiri R, Bright S, Schaffer B, Medina LD,
et al. Cortical event-related potentials in preclinical familial Alz-
heimer disease. Neurology 2009;73:1649–55.
[6] Quiroz YT, Ally BA, Celone K, McKeever J, Ruiz-Rizzo AL,
Lopera F, et al. Event-related potential markers of brain changes in
preclinical familial Alzheimer disease. Neurology 2011;77:469–75.
[7] Bennys K, Rondouin G, Benattar E, Gabelle A, Touchon J. Can event-
related potential predict the progression of mild cognitive impairment?
J Clin Neurophysiol 2011;28:625–32.
[8] Olichney JM, Taylor JR, Gatherwright J, Salmon DP, Bressler AJ,
Kutas M, et al. Patients with MCI and N400 or P600 abnormalities
are at very high risk for conversion to dementia. Neurology 2008;
70:1763–70.
[9] Papaliagkas VT, Kimiskidis VK, Tsolaki MN, Anogianakis G. Cogni-
tive event-related potentials: Longitudinal changes in mild cognitive
impairment. Clin Neurophysiol 2011;122:1322–6.
[10] Lai CL, Lin RT, Liou LM, Liu C-K. The role of event-related poten-
tials in cognitive decline in Alzheimer’s disease. Clin Neurophysiol
2010;121:194–9.
[11] Werber AE, Klein C, Rabey JM. Evaluation of cholinergic treatment in
demented patients by P300 evoked related potentials. Neurol Neuro-
chir Pol 2001;35(Suppl 3):37–43.
[12] Onofrj M, Thomas A, Luciano AL, Iacono D, Di Rollo A,
Andreamatteo GD, et al. Donepezil versus vitamin E in Alzheimer’s
disease: Part 2: Mild versus moderate–severe Alzheimer’s disease.
Clin Neuropharmacol 2002;25:207–15.
[13] Takano M, Watanabe Y, Hoshino Y, Izawa N, Kawakami T, Tanaka H,
et al. Effects of memantine on event-related potentials in Alzheimer’s
disease under donepezil treatment. Neurosci Biomed Eng 2013;
1:34–9.
[14] Jackson CE, Snyder PJ. Electroencephalography and event-related po-
tentials as biomarkers of mild cognitive impairment and mild Alz-
heimer’s disease. Alzheimer’s Dement 2008;4:S137–43.
[15] Olichney JM, Yang J-C, Taylor J, Kutas M. Cognitive event-
related potentials: Biomarkers of synaptic dysfunction across
the stages of Alzheimer’s disease. J Alzheimer’s Dis 2011;
26(Suppl 3):215–28.
[16] Vecchio F, M€a€att€a S. The use of auditory event-related potentials in
Alzheimer’s disease diagnosis. Int J Alzheimers Dis 2011;
2011:1–7.
[17] McKhann G, Drachman D, Folstein M, Katzman R, Price D,
Stadlan EM. Clinical diagnosis of Alzheimer’s disease—Report of
the NINCDS-ADRDAWork Group under the auspices of Department
of Health and Human Services Task Force on Alzheimer’s disease.
Neurology 1984;34:939–44.
[18] Polich J. Clinical application of the P300 event-related brain potential.
Phys Med Rehabil Clin N Am 2004;15:133–61.
[19] Polich J. Neuropsychology of P300. In: . NewYork, NewYork: Oxford
University Press; 2012. p. 159–88.
[20] Henry EA, Kaye JT, Bryan AD, Hutchison KE, Ito TA. Cannabis cue
reactivity and craving among never, infrequent and heavy cannabis
users. Neuropsychopharmacology 2014;39:1214–21.
M. Cecchi et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 387-394 393
[21] Jasper H. The ten twenty electrode system of the international federa-
tion. Electroencephalogr Clin Neurophysiol 1958;10:371–5.
[22] Duncan CC, Barry RJ, Connolly JF, Fischer C,Michie PT, N€a€at€anen R,
et al. Event-related potentials in clinical research: Guidelines for elic-
iting, recording, and quantifying mismatch negativity, P300, and
N400. Clin Neurophysiol 2009;120:1883–908.
[23] Gonsalvez CL, Polich J. P300 amplitude is determined by target-to-
target interval. Psychophysiology 2002;39:388–96.
[24] Golob E, Starr A. Effects of stimulus sequence on event-related poten-
tials and reaction time during target detection in Alzheimer’s disease.
Clin Neurophysiol 2000;111:1438–49.
[25] Pontifex MB, Hillman CH, Polich J. Age, physical fitness, and atten-
tion: P3a and P3b. Psychophysiology 2009;46:379–87.
[26] Yamaguchi S, Tsuchiya H, Yamagata S, Toyoda G, Kobayashi S.
Event-related brain potentials in response to novel sounds in dementia.
Clin Neurophysiol 2000;111:195–203.
[27] Luck SJ. An introduction to the event-related potential technique.
Cambridge, Massachusetts: The MIT Press; 2005.
[28] Polich J. Updating P300: An integrative theory of P3a and P3b. Clin
Neurophysiol 2007;118:2128–48.
[29] Donchin E, Coles MG. Is the P300 component a manifestation of
context updating? Behav Brain Sci 1988;11:357.
[30] Duncan-Johnson CC, Donchin E. The P300 component of the event-
related brain potential as an index of information processing. Biol Psy-
chol 1982;14:1–52.
[31] Kutas M, McCarthy G, Donchin E. Augmenting mental chronometry:
The P300 as a measure of stimulus evaluation time. Science 1977;
197:792–5.
[32] Polich J, Corey-bloom J. Alzheimer’s disease and P300: Review and
evaluation of task and modality. Curr Alzheimer Res 2005;
300:515–25.
[33] Patel SH, Azzam PN. Characterization of N200 and P300:
Selected studies of the event-related potential. Int J Med Sci
2005;2:147–54.
[34] Bennys K, Portet F, Touchon J. Diagnostic value of event-related
evoked potentials N200 and P300 subcomponents in early diagnosis
of Alzheimer’s disease and mild cognitive impairment. J Clin Neuro-
physiol 2007;24:405–12.
[35] Ruchkin DS, Johnson R, Mahaffey D, Sutton S. Toward a functional
categorization of slow waves. Psychophysiology 1988;25:339–53.
[36] Frodl T, Hampel H, Juckel G, B€urger K, Padberg F, Engel RR, et al.
Value of event-related P300 subcomponents in the clinical diagnosis
of mild cognitive impairment and Alzheimer’s disease. Psychophysi-
ology 2002;39:175–81.
[37] Juckel G, Clotz F, Frodl T, Kawohl W, Hampel H, Pogarell O, et al.
Diagnostic usefulness of cognitive auditory event-related P300 sub-
components in patients with Alzheimers disease? J Clin Neurophysiol
2008;25:147–52.
[38] Fjell AM, Walhovd KB. P300 and neuropsychological tests as mea-
sures of aging: Scalp topography and cognitive changes. Brain Topogr
2001;14:25–40.
[39] Baudic S, Barba GD, Thibaudet MC, Smagghe A, Remy P, Traykov L.
Executive function deficits in early Alzheimer’s disease and their rela-
tions with episodic memory. Arch Clin Neuropsychol 2006;21:15–21.
[40] Caselli RJ, Dueck AC, Locke DE, Hoffman-Snyder CR,Woodruff BK,
Rapcsak SZ, et al. Longitudinal modeling of frontal cognition in
APOE 34 homozygotes, heterozygotes, and noncarriers. Neurology
2011;76:1383–8.
[41] Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K,
et al. Effect of amyloid on memory and non-memory decline from pre-
clinical to clinical Alzheimer’s disease. Brain 2014;137:221–31.
[42] Spreng M. Influence of impulsive and fluctuating noise upon physio-
logical excitations and short-time readaptation. Scand Audiol Suppl
1980;:299–306.
[43] Davis H, Mast T, Yoshie N, Zerlin S. The slow response of the human
cortex to auditory stimuli: Recovery process. Electroencephalogr Clin
Neurophysiol 1966;21:105–13.
[44] Hillyard SA, Hink RF, Schwent VL, Picton TW. Electrical signs of se-
lective attention in the human brain. Science 1973;182:177–80.
[45] Golob E, Starr A. Age-related qualitative differences in auditory
cortical responses during short-term memory. Clin Neurophysiol
2000;111:2234–44.
[46] Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The
topographical and neuroanatomical distribution of neurofibrillary tan-
gles and neuritic plaques in the cerebral cortex of patients with Alz-
heimer’s disease. Cereb Cortex 1991;1:103–16.
[47] Alexander GE, Newman JD, Symmes D. Convergence of prefrontal
and acoustic inputs upon neurons in the superior temporal gyrus of
the awake squirrel monkey. Brain Res 1976;116:334–8.
[48] Metherate R, Ashe JH. Nucleus basalis stimulation facilitates thalamo-
cortical synaptic transmission in the rat auditory cortex. Synapse 1993;
14:132–43.
[49] Key AP, Dove GO, Maguire MJ. Linking brainwaves to the brain: An
ERP primer. Dev Neuropsychol 2005;27:183–215.
M. Cecchi et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 387-394394
